

Grace Therapeutics, Inc.

(GRCE: NASDAQ)

GRCE: Looking Ahead to Acceptance

Grace's valuation relies on a DCF model and a 15% discount rate applied to our cash flow estimates. Additionally, we apply an 85% probability of commercial success to the GTX-104 program. The adjustment recognizes regulatory and commercialization risks. The model includes contributions from the United States and the developed world.

Current Price (8/13/2025) **\$3.30**
Valuation \$12.50

OUTLOOK

Grace is a clinical-stage, biotechnology company focused on rare disease. Its lead program, GTX-104, is a novel injectable formulation of nimodipine for the treatment of aneurysmal subarachnoid hemorrhage (aSAH). Other programs include GTX-102 for Ataxia Telangiectasia & GTX-101 for postherpetic neuralgia. GTX-104 is formulated from a previously approved product and a patented technology that employs non-ionic surfactant micelles to overcome delivery shortcomings.

Nimodipine is a lipophilic calcium channel blocker that has been shown to be effective in improving outcomes following aSAH surgery. Its FDA approved oral formulation presents several drawbacks especially for patients who have difficulty swallowing. An IV formulation using safe excipients can address many of these challenges and is represented by GTX-104.

GTX-104 has reported data from its pivotal Phase III safety trial and has been submitted in an NDA to the FDA. Other candidates are ready for Phase III (GTX-102) & Phase II (GTX-101) and are available for partnering or further development if additional capital becomes available.

SUMMARY DATA

52-Week High **4.97**
 52-Week Low **1.75**
 One-Year Return (%) **37.2**
 Beta **0.9**
 Average Daily Volume (sh) **55,074**

Shares Outstanding (mil) **16.4**
 Market Capitalization (\$mil) **53.8**
 Short Interest Ratio (days) **1.2**
 Institutional Ownership (%) **29.2**
 Insider Ownership (%) **30.3**

Annual Cash Dividend **\$0.00**
 Dividend Yield (%) **0.00**

5-Yr. Historical Growth Rates
 Sales (%) **N/A**
 Earnings Per Share (%) **N/A**
 Dividend (%) **N/A**

P/E using TTM EPS **N/A**
 P/E using 2025 Estimate **N/A**
 P/E using 2026 Estimate **N/A**

Zacks Rank **N/A**

Risk Level **Above Average**
 Type of Stock **Small-Growth**
 Industry **Med-Biomed/Gene**

ZACKS ESTIMATES

Revenue

(In millions of US\$)

	Q1	Q2	Q3	Q4	Year
	(Jun)	(Sep)	(Dec)	(Mar)	(Mar)
2025	\$0.0 A				
2026	\$0.0 A	\$0.0 E	\$0.0 E	\$0.0 E	\$0.0 E
2027					\$1.4 E
2028					\$10.1 E

Earnings per Share

	Q1	Q2	Q3	Q4	Year
	(Jun)	(Sep)	(Dec)	(Mar)	(Mar)
2025	-\$0.24 A	-\$0.30 A	-\$0.36 A	\$0.05 A	-\$0.79 A
2026	-\$0.21 A	-\$0.12 A	-\$0.09 A	-\$0.13 A	-\$0.55 E
2027					-\$1.01 E
2028					-\$0.63 E

What's New?

Grace Therapeutics, Inc (NASDAQ: GRCE) [reported](#) first quarter fiscal year 2026 results highlighting the recent submission of its new drug application (NDA) for GTx-104. GTx-104 is an infused formulation of nimodipine developed to treat patients with aneurysmal subarachnoid hemorrhage (aSAH). The company [announced](#) that it had submitted its new drug application (NDA) to the FDA on June 25th. This is a meaningful milestone for the company and may trigger the release of additional capital if the NDA is accepted. We expect the FDA to announce its acceptance in the August 2025 timeframe. As a reminder, in February the company announced results for the Phase III STRIVE-ON trial. It found excellent relative dose intensity, better outcomes, fewer intensive care unit readmissions and fewer ventilator days for patients on GTx-104 compared with oral nimodipine.

Fiscal Year 1Q:26 Financial and Operational Results

Grace reported 1Q:26 results in a [press release](#) and a [Form 10-Q](#) filing with the SEC on August 12th. For the three-month period ending June 30th, 2025, operating expenses of \$3.1 million were recognized. Net loss for 1Q:26 totaled (\$3.4) million or (\$0.21) per share. Comparing the fiscal first quarter 2026 to the same prior year period:

- General & Administrative expenses were \$2.1 million, down 5% from \$2.3 million. The change was attributable to lower professional fees;
- Research and development expenses fell by 65% to \$1.0 million from \$2.7 million as the clinical development program for GTx-104 concluded;
- Net interest and other income were (\$0.3) million compared to \$1.6 million with the difference primarily related to a change in fair value of derivative warrant liabilities related to an increase in Grace's stock price. Interest income fell due to a lower interest yield;
- Net loss was (\$3.4) million vs. (\$2.6) million or (\$0.21) per share vs (\$0.24).

As of June 30th, 2025, cash and equivalents carried on the balance sheet totaled \$20.0 million. This amount compares to the \$22.1 million cash balance held at the end of fiscal year 2025. Net cash used in financing for 1Q:26 was \$327,000 million related to stock issuance costs.

New Drug Application (NDA) Submission

As expected, Grace Therapeutics submitted its new drug application (NDA) to the FDA before the end of the calendar second quarter. Following the pre-NDA meeting held with the FDA earlier in the year, management felt closely aligned with the agency in terms of NDA acceptance requirements. It spent the next several months preparing the related documents and on June 24th announced that it had submitted its application.

Grace is in a strong financial position with \$20 million in cash as of June 30th, 2025 and offers a product that meets a profound unmet need. During previous equity capital raises, Grace was able to structure these deals so that the attached warrants could be called upon after achieving certain milestones. The company will be able to demand exercise of warrants that can potentially generate about \$7.6 million following NDA acceptance and about \$15 million following approval of GTx-104 assuming the warrants are in the money. Following normal regulatory timelines, the first milestone could be reached in August if the FDA accepts the application.

With the funds on the balance sheet and additional capital raised from the warrant exercises, Grace will be able to begin commercialization activities. Its plan is to focus on the top 250 to 300 hospitals that address aneurysmal subarachnoid hemorrhage (aSAH), which is achievable with a sales force of 15 to 20. We expect to hear more about the strategy in the coming months and following the conclusion of marketing studies the company is conducting.

Grace Therapeutics Investment Thesis

In support of the reiteration of the thesis for the company, we recorded a short [clip](#) highlighting reasons to own Grace Therapeutics.

Exhibit I – Reasons to Own Grace Therapeutics




Source: Screenshot from Analyst Video

Investment Thesis

Grace’s GTx-104 investment thesis is straightforward. There are about 40,000 aSAH cases per year in the United States that in many cases are inadequately served. Oral nimodipine is standard of care. The underlying drug has demonstrated its efficacy in increasing blood flow to the brain, reducing brain damage and improving neurological outcomes. However, nimodipine is only available in oral form which presents several shortcomings. The primary weakness is that the oral formulation is difficult to administer to patients that are unconscious or have a hard time swallowing, which is a common feature of aSAH patients. Oral nimodipine should be administered every four hours due to its short half-life and it should not be taken with food as this further reduces its already low bioavailability. Oral nimodipine has low and inconsistent bioavailability due to first-pass metabolism and poor solubility, resulting in reduced systemic exposure. Higher blood plasma levels can cause hypotension which is associated with neurological impairment, organ damage, reduced kidney function and other risks. Europe offers an IV formulation of nimodipine branded Nimotop; however, the product solubilizes the drug with high levels of ethanol and propylene glycol. These excipients have numerous negative effects and prevented FDA approval of Nimotop. Grace’s IV formulation uses excipients generally recognized as safe (GRAS), and provides a product which is able to improve upon the ethanol-based European version and the oral formulation’s primary weaknesses.

Exhibit II – Concentration of aSAH Care



aSAH-Treating Institutions Concentration			
% aSAH Patients	% of Institutions	# of Institutions	Est. Sales Reps ¹
40%	~4%	146	~10
50%	~7%	242	~15
60%	~11%	380	~25



Source: Grace Therapeutics Overview, Summer 2025

Results from Grace's Phase III safety trial found excellent relative dose intensity, better outcomes, fewer intensive care unit readmissions and fewer ventilator days for GTx-104 compared with oral nimodipine. The trial met its primary endpoint of the number of patients with at least one episode of clinically significant hypotension reasonably considered to be caused by the drug. Patients receiving GTx-104 experienced a 19% reduction in at least one incidence of clinically significant hypotension compared to oral nimodipine (28% versus 35%). Secondary endpoints include safety, clinical and pharmacoeconomic outcomes. Additional detail on the trial can be found in Grace's [press release](#) and in our [report](#).

Valuation

We assign Grace a \$12.50 valuation which provides upside of almost 4x. It is a relatively lower risk development play as the underlying drug is already approved, the new formulation addresses significant unmet needs and all of the development work is complete, generating compelling results. While the company plans to develop GTx-104 itself, we think that additional value could be recognized if an established pharmaceutical company buys the asset and folds it into its operations.

Milestones

- Pre-NDA meeting with FDA – 2Q:25
- NDA submission to FDA – June 2025
- \$7.6 million warrant exercise if NDA accepted & above \$3.00 strike – Fall 2025
- Target Action Date – mid-2026
- \$15 million warrant exercise if GTx-104 approved & above \$3.39 – Fall 2026
- GTx-104 commercialization – late 2026

Resources

- Initiating Coverage – [From Confusion to Infusion](#) – November 2024
- [aSAH key opinion leader summary](#) – December 2024
- [STRIVE-ON results](#) – February 2025

Summary

Grace released fiscal first quarter 2026 results and summarized recent accomplishments in its earnings report and Form 10-Q filing. The most important event is the NDA submission and its anticipated acceptance by the FDA in the next few weeks. We look ahead to future milestones including warrant exercises around FDA actions including approval which may occur in spring 2026. We think there is a strong investment thesis for the company as Grace is valued at about \$50 million, with almost 40% of this value in cash on the balance sheet. The company holds no debt and has submitted its NDA to the FDA. We think product sales could peak at several hundred million dollars, which suggests substantial upside even with a low single-digit multiple of sales. GTx-104 addresses many of the shortcomings of oral nimodipine in treating aSAH. We believe it will be well-received by hospitals, as it can significantly improve outcomes and help them maintain their reputations and stroke center certifications. We maintain our valuation of \$12.50 per share.

PROJECTED FINANCIALS


Grace Therapeutics, Inc. - Income Statement

Grace Therapeutics, Inc.	2025 A	Q1 A	Q2 E	Q3 E	Q4 E	2026 E	2027 E	2028 E
Total Revenues (\$USD)	\$0	\$0	\$0	\$0	\$0	\$0	\$1,363	\$10,057
Research & Development	\$9,511	\$955	\$700	\$600	\$545	\$2,800	\$2,000	\$2,200
General & Administrative	\$7,168	\$2,135	\$1,892	\$1,580	\$1,622	\$7,229	\$8,000	\$8,800
Sales & Marketing	\$0	\$0	\$0	\$200	\$800	\$1,000	\$12,500	\$13,750
Income from Operations	(\$16,679)	(\$3,090)	(\$2,592)	(\$2,380)	(\$2,967)	(\$11,029)	(\$21,137)	(\$14,693)
Other Items	\$3,201	(\$477)	\$0	\$0	\$0	\$0	\$0	\$0
Net Interest Expense	\$711	\$205	\$180	\$180	\$150	\$0	\$0	\$0
Pre-Tax Income	(\$12,767)	(\$3,362)	(\$2,412)	(\$2,200)	(\$2,817)	(\$11,029)	(\$21,137)	(\$14,693)
Provision for Income Tax	\$3,199	\$0	\$500	\$500	\$544	\$1,544	\$2,959	\$2,057
<i>Tax Rate</i>	<i>-25.1%</i>	<i>0.0%</i>	<i>-20.7%</i>	<i>-22.7%</i>	<i>-19.3%</i>	<i>-14.0%</i>	<i>-14.0%</i>	<i>-14.0%</i>
Net Income	(\$9,568)	(\$3,362)	(\$1,912)	(\$1,700)	(\$2,273)	(\$9,485)	(\$18,178)	(\$12,636)
<i>Net Margin</i>								
Reported EPS	(\$0.79)	(\$0.21)	(\$0.12)	(\$0.09)	(\$0.13)	(\$0.55)	(\$1.01)	(\$0.63)
<i>YOY Growth</i>								
Basic Shares Outstanding	12,087	15,925	16,500	18,000	18,000	17,106	18,000	20,000

Source: Company Filing // Zacks Investment Research, Inc. Estimates

HISTORICAL STOCK PRICE

Grace Therapeutics, Inc. – Share Price Chart¹



¹ Source: Zacks Research System

DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, John Vandermosten, hereby certify that the views expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.

Zacks SCR has received compensation from the issuer directly, from an investment manager or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.

SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover.

SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.